

# Vivek Chand Goodoory

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9719500/publications.pdf>

Version: 2024-02-01

10  
papers

134  
citations

1684188

5  
h-index

1720034

7  
g-index

10  
all docs

10  
docs citations

10  
times ranked

26  
citing authors

#	ARTICLE	IF	CITATIONS
1	Direct healthcare costs of Rome <scp>IV</scp> or Rome <scp>III</scp>â€defined irritable bowel syndrome in the United Kingdom. Alimentary Pharmacology and Therapeutics, 2022, 56, 110-120.	3.7	37
2	Impact of Rome IV irritable bowel syndrome on work and activities of daily living. Alimentary Pharmacology and Therapeutics, 2022, 56, 844-856.	3.7	30
3	Impact of Psychological Comorbidity on the Prognosis of Irritable Bowel Syndrome. American Journal of Gastroenterology, 2021, 116, 1485-1494.	0.4	24
4	Natural History and Disease Impact of Rome IV Vs Rome III Irritable Bowel Syndrome: A Longitudinal Follow-Up Study. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	22
5	Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2022, 55, 1311-1319.	3.7	16
6	Characteristics of, and natural history among, individuals with Rome IV functional bowel disorders. Neurogastroenterology and Motility, 2022, 34, e14268.	3.0	4
7	Prognosis of patients with Rome IVâ€defined versus physicianâ€diagnosed irritable bowel syndrome: Longitudinal followâ€up study. Neurogastroenterology and Motility, 2021, , e14282.	3.0	1
8	Efficacy of Senna and Magnesium Oxide for the Treatment of Chronic Idiopathic Constipation. American Journal of Gastroenterology, 2021, 116, 1352-1353.	0.4	0
9	Editorial: risky business. What do sufferers' perceptions of risk from interventions for IBS really mean? Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 1220-1221.	3.7	0
10	Editorial: estimating the costs of care in irritable bowel syndromeâ€”a necessary step to enhance valueâ€based care for a highâ€prevalence, lowâ€cost condition. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 1590-1591.	3.7	0